Bio-Techne (TECH) Net Cash Flow Growth (3y) (2012 - 2026)
Powered by 
Analysis
Bio-Techne (TECH) Net Cash Flow Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 4.55% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 52.78% |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn | 0.45% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.45% |
| Mar 31, 2026 | 43.58% |
| Dec 31, 2025 | 76.23% |
| Sep 30, 2025 | -76.42% |
| Jun 30, 2025 | -23.78% |
| Mar 31, 2025 | 8.63% |
| Dec 31, 2024 | -33.20% |
| Sep 30, 2024 | 165.87% |
| Jun 30, 2024 | -19.85% |
| Mar 31, 2024 | -15.03% |
| Dec 31, 2023 | -32.61% |
| Sep 30, 2023 | -44.42% |
| Jun 30, 2023 | 93.38% |
| Mar 31, 2023 | -40.58% |
| Dec 31, 2022 | -47.12% |
| Sep 30, 2022 | 57.01% |
| Jun 30, 2022 | 47.56% |
| Mar 31, 2022 | -99.61% |
| Dec 31, 2021 | 51.89% |
| Sep 30, 2021 | 27.29% |